Codiak BioSciences, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Douglas Edward Williams
- Full Time Employees
- 102
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 35 Cambridge Park Drive Cambridge MA United States of America 02140
- IPO Date
- Oct 14, 2020
- CIK
- 0001659352
- Website
- codiakbio.com
- Similar Companies
- Business
- Codiak BioSciences, Inc. formerly operated as a clinical-stage biopharmaceutical firm, dedicated to advancing exosome-based therapeutic interventions for a diverse array of conditions, including various cancers, neuro-oncological disorders, neurological and neuromuscular ailments, and infectious diseases. The company’s pipeline featured lead candidates such as exoSTING and exoIL-12, engineered exosome therapeutics targeting solid tumors. Additionally, Codiak was developing exoASO-STAT6, an antisense oligonucleotide designed to influence the STAT6 transcription factor, and exoVACC, a adaptable platform intended for the construction of precision vaccines. Leveraging its proprietary engEx platform, the company aimed to create a new class of medicines by precisely engineering exosomes for targeted drug delivery. Codiak BioSciences had established collaboration agreements with entities including Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, and the Ragon Institute of MGH, MIT, and Harvard. The organization, founded in 2015 and based in Cambridge, Massachusetts, voluntarily initiated Chapter 11 bankruptcy proceedings in March 2023 and was subsequently delisted from Nasdaq, transitioning to trade on OTC markets as CDAKQ, with a focus on pursuing the sale of its assets.
Why Is Codiak BioSciences (CDAK) Stock Down 52% Today?
Codiak BioSciences files for bankruptcy, looks to sell off assets
Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue Estimates
Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting Macrophages
Codiak BioSciences, Inc. (CDAK) Reports Q2 Loss, Tops Revenue Estimates
Codiak BioSciences' Engineered Exosome Candidates Show Early Antitumor Activity
Codiak BioSciences, Inc. (CDAK) Reports Q1 Loss, Tops Revenue Estimates
Codiak BioSciences, Inc. (CDAK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 700% Upside Potential
Codiak BioSciences, Inc. (CDAK) Reports Q4 Loss, Tops Revenue Estimates
Codiak BioSciences, Inc. (CDAK) Stock Jumps 18.2%: Will It Continue to Soar?
Codiak BioSciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
Codiak BioSciences (CDAK) Stock: Why The Price Jumped Today
Codiak BioSciences to Present at the 4th Annual Evercore ISI HealthCONx Conference
Codiak BioSciences' Exosome Candidate Shows Tumor Shrinkage In Early Study
Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Misses Revenue Estimates
Codiak to Present Preclinical Data Demonstrating New Potential Therapeutic Applications of Engineered Exosomes at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Codiak BioSciences Appoints Lini Pandite, MBChB, MBA to Board of Directors
Codiak BioSciences to Present at the Virtual William Blair Biotech Focus Conference 2021
Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles